Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Carl Stubbings, CEO and MD of Sienna Cancer Diagnostics (ASX:SDX).

Sienna is focused on developing tests for ‘liquid biopsies’ – diagnosing blood and urine samples for the biomarkers that indicate the presence of cancer.

The company’s first product is aimed at detecting a biomarker called H-TERT, which is evident in bladder cancers.

It’s also developing a kit that ‘cleans’ liquid samples ahead of analysis, thus producing more reliable results.

So tune in to hear the pair discuss the Swine Flu pandemic, exosome therapeutics and ASX life-sciences hurdles.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!